Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

semaglutide

Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme

DRUG

placebo

Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.

DRUG

Microgyn®

Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01324505 - Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter